Manraj Singh Sra, MBBS

2026

• Cost-effectiveness analysis of fosaprepitant versus aprepitant-based antiemetic regimens in children receiving highly emetogenic chemotherapy: individual patient-level analysis of a randomised trial.

  Kumar R, Sra M, Rasheed A, Sasi A, Pushpam D, Batra A, Ganguly S, Bakhshi S. Cost-effectiveness analysis of fosaprepitant versus aprepitant-based antiemetic regimens in children receiving highly emetogenic chemotherapy: individual patient-level analysis of a randomised trial. BMJ Supportive & Palliative Care 2026, spcare-2026-006355. PMID: 42660630, DOI: 10.1136/spcare-2026-006355.

  Peer-Reviewed Original Research

• Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds

  Wang D, Sra M, Ng D, Tadepalli A, Rinaldi K, Ito S, Cuker A, Goshua G. Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds. Blood Advances 2026, 10: 5644-5652. PMID: 42206692, PMCID: PMC13499173, DOI: 10.1182/bloodadvances.2026020143.

  Peer-Reviewed Original Research

  Citations

• Motorized travel time to access childhood cancer care in India: A multi-center geospatial analysis

  Singh M, Aksithanand K, Ganguly S, Radhakrishnan V, Swaminathan R, Kapoor G, Bakhshi S, Zadey S, Sharma P. Motorized travel time to access childhood cancer care in India: A multi-center geospatial analysis. Journal Of Cancer Policy 2026, 49: 100786. PMID: 42498027, DOI: 10.1016/j.jcpo.2026.100786.

  Peer-Reviewed Original Research

  MeSH Keywords

• Duffy Testing to Benefit Children’s Population Health: A Cost-Effectiveness Analysis

  Merz L, Ito S, Sra M, Ng D, Walkovich K, Okam Achebe M, Frustace P, van Havre N, Goshua G. Duffy Testing to Benefit Children’s Population Health: A Cost-Effectiveness Analysis. Blood Advances 2026 PMID: 42486669, DOI: 10.1182/bloodadvances.2026019827.

  Peer-Reviewed Original Research

• Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma

  Singh M, Kumar S. Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma. Expert Opinion On Biological Therapy 2026, 26: 665-676. PMID: 42434875, DOI: 10.1080/14712598.2026.2703858.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

  Altmetric

  MeSH Keywords

• Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis

  Chetlapalli K, Ito S, Ng D, Sra M, Wang D, Krumholz H, Krishnamurti L, Pandya A, Goshua G. Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis. Blood 2026, 148: 896-909. PMID: 42227898, PMCID: PMC13507984, DOI: 10.1182/blood.2025032290.

  Peer-Reviewed Original Research

  This study investigates the cost-effectiveness of haploidentical stem cell transplantation, gene therapy, and standard care for sickle cell disease, showing transplantation offers the best value globally.

  Full Summary

• Association of longitudinal changes in nutritional status with survival outcomes in childhood cancer

  Sra M, Ganguly S, Sasi A, Bansal A, Verma V, Sharma S, Kumari M, Pushpam D, Batra A, Agarwala S, Bakhshi S. Association of longitudinal changes in nutritional status with survival outcomes in childhood cancer. Clinical Nutrition 2026, 63: 106704. PMID: 42296830, DOI: 10.1016/j.clnu.2026.106704.

  Peer-Reviewed Original Research

• Monoclonal gammopathy of clinical significance: a multisystem review

  Sra M, Rajkumar S, Kumar S. Monoclonal gammopathy of clinical significance: a multisystem review. Blood Cancer Journal 2026, 16: 128. PMID: 42215470, PMCID: PMC13424114, DOI: 10.1038/s41408-026-01528-5.

  Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

  Citations

  Altmetric

• Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia

  Ito S, Potnis K, Ng D, Patel K, Sra M, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia. Blood Red Cells & Iron 2026, 2: 100076. PMID: 42077391, PMCID: PMC13134686, DOI: 10.1016/j.brci.2026.100076.

  Peer-Reviewed Original Research

  This study investigates how trainee-led teams developed updated consensus guidelines for managing peritoneal surface malignancies, demonstrating effective collaboration models for complex medical evidence synthesis.

  Full Summary

• Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator‐Initiated Randomized, Open‐Label, Non‐Inferiority Trial

  Rasheed A, Ganguly S, Singh M, Kumar S, Batra A, Pushpam D, Vishnubhatla S, Pillai A, Joison A, Sharma S, Bakhshi S. Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator‐Initiated Randomized, Open‐Label, Non‐Inferiority Trial. Pediatric Blood & Cancer 2026, 73: e70171. PMID: 41823195, DOI: 10.1002/1545-5017.70171.

  Peer-Reviewed Original Research

  Citations

  Altmetric

  MeSH Keywords